Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 6/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | IDO1 | P14902 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA7 | P43166 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | ENPP3 | O14638 | 1/20 | 0.38 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.38 |
| ▸ | KIF11 | P52732 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 3/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12960035 | 1.00 | ACHE (0.50) | ACHETDP1IDO1ALDH1A1CA1 | |
| SCHEMBL72612 | 0.90 | — | — | |
| Water SCHEMBL28465047 | 0.87 | ACHE (0.57) | ACHETDP1IDO1ALDH1A1CA1 | |
| Water SCHEMBL28352804 | 0.87 | — | — | |
| SCHEMBL28998886 | 0.87 | — | — | |
| SCHEMBL2209060 | 0.87 | ACHE (0.57) | ACHETDP1IDO1ALDH1A1CA1 | |
| SCHEMBL1995481 | 0.87 | — | — | |
| Hydrochloric Acid SCHEMBL9581207 | 0.87 | — | — | |
| SCHEMBL5302850 | 0.87 | — | — | |
| SCHEMBL6514380 | 0.87 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 102 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122036798-A | Gold (I) complex containing benzene ring ligand, preparation method thereof and application thereof in preparation of antitumor drugs | 西南医科大学附属医院 | 2026-05-15 | — | — | CN | claimed |
| CN-117899093-A | Pharmaceutical use of 4-tolylthiophenol diphenyl-2-pyridinium phosphine alloy (I) | 电子科技大学 | 2024-04-19 | — | — | CN | claimed |
| CN-122036798-A | Gold (I) complex containing benzene ring ligand, preparation method thereof and application thereof in preparation of antitumor drugs | 西南医科大学附属医院 | 2026-05-15 | — | — | CN | disclosed |
| CN-119314944-A | Inhibitor, method for regioselective deposition, chip and method for manufacturing chip | 华为技术有限公司 | 2025-01-14 | — | — | CN | disclosed |
| CN-107022329-B | Aqueous adhesive composition and use thereof | 日东电工株式会社 | 2024-05-28 | — | — | CN | disclosed |
| WO-2024092039-A1 | COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF | MONTE ROSA THERAPEUTICS, INC. (US) | 2024-05-02 | — | — | WO | disclosed |
| CN-117899093-A | Pharmaceutical use of 4-tolylthiophenol diphenyl-2-pyridinium phosphine alloy (I) | 电子科技大学 | 2024-04-19 | — | — | CN | disclosed |
| CN-117899093-A | Pharmaceutical use of 4-tolylthiophenol diphenyl-2-pyridinium phosphine alloy (I) | 电子科技大学 | 2024-04-19 | — | — | CN | disclosed |
| CN-117899093-A | Pharmaceutical use of 4-tolylthiophenol diphenyl-2-pyridinium phosphine alloy (I) | 电子科技大学 | 2024-04-19 | — | — | CN | disclosed |
| CN-110007557-B | Curable composition, film, optical film, light-emitting display element panel, and light-emitting display device | 东京应化工业株式会社 | 2024-04-12 | — | — | CN | disclosed |
| CN-117143287-B | Sulfur-containing polymer, preparation method, negative electrode plate, secondary battery and electricity utilization device | 宁德时代新能源科技股份有限公司 | 2024-04-09 | — | — | CN | disclosed |
| US-7196214-B2 | Process for arylamine production | XEROX CORPORATION (US) | 2007-03-27 | — | — | US | disclosed |
| US-20070065741-A1 | Electrophotographic photoreceptor, process cartridge, and image forming apparatus | FUJI XEROX CO., LTD. (JP) | 2007-03-22 | — | — | US | disclosed |
| US-20070065741-A1 | Electrophotographic photoreceptor, process cartridge, and image forming apparatus | FUJI XEROX CO., LTD. (JP) | 2007-03-22 | — | — | US | disclosed |
| US-20070010489-A1 | Cellular accumulation of phosphonate analogs of hiv protease inhibitor compounds | GILEAD SCIENCES, INC. | 2007-01-11 | — | — | US | disclosed |
| US-6645293-B2 | Molecular crystals of controlled size | ILLINOIS INSTITUTE OF TECHNOLOGY | 2003-11-11 | — | — | US | disclosed |
| WO-2003076697-A1 | MOLECULAR CRYSTALS OF CONTROLLED SIZE | ILLINOIS INSTITUTE OF TECHNOLOGY (US) | 2003-09-18 | — | — | WO | disclosed |
| US-20030170999-A1 | MOLECULAR CRYSTALS OF CONTROLLED SIZE | ILLINOIS INSTITUTE OF TECHNOLOGY | 2003-09-11 | — | — | US | disclosed |
| US-20030068252-A1 | Crystal nucleating chip | BRISTOL-MYERS SQUIBB COMPANY | 2003-04-10 | — | — | US | disclosed |
| WO-1989003416-A1 | FERROELECTRIC LIQUID CRYSTALLINE PHASES | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 1989-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010489-A1 | Cellular accumulation of phosphonate analogs of hiv protease inhibitor compounds | PPA1, PNP, PPME1 | ACHE 1764/4885TDP1 607/4885IDO1 2558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.